Table 1.

Safety experience of dual biological therapy in Crohn’s disease

Case	Disease	Dual biological regimen	Duration of dual biological therapy	Adverse events	Crohn’s disease status
1	Ileocolonic Crohn’s disease, ankylosing spondylitis	Etanercept and vedolizumab	20 months	None	Active
		Etanercept and ustekinumab	2 months	None
2	Colonic and perianal Crohn’s disease	Vedolizumab and ustekinumab	5 months	Two Clostridium difficile infections	Clinical remission
3	Ileocolonic and perianal Crohn’s disease	Vedolizumab and golimumab	8 months	None	Clinical remission
4	Ileocolonic and perianal Crohn’s disease	Vedolizumab, golimumab and 6-mercaptopurine	37 months	Hand-foot-mouth disease and influenza	Clinical remission